The Department of Health and Human Services Food and Drug Administration awarded a single-award Indefinite Delivery Contract to Illumina, Inc. with a potential value of $25 million. The contract provides Illumina Reagent Chemistry Kits to support the FDA's laboratory testing needs across multiple places of performance from November 2022 through January 2028.
Task orders issued against the IDV by the FDA to Illumina total over $3.5 million and include delivery of reagent kits to locations such as Laurel, MD, Berwyn Heights, MD, Atlanta, GA, Ithaca, NY, and Jefferson, AR. The kits are utilized in the FDA's regulatory and research programs involving genomic and analytical chemistry analysis to advance medical product safety evaluations, modernize pre-market review, and protect public health. Task orders are fixed-price, with performance periods ranging from one month to over four years, and are issued under the IDV on an as-needed basis to meet the FDA's scientific supply demands.
The original IDV and follow-on task orders procure Illumina's proprietary reagent kits, consumables, and services to support the FDA's application of next-generation sequencing and genomic technologies for evaluating drugs, biologics, and devices. The award allows the agency to leverage commercial innovations and maintain independent testing capabilities that are critical to its mission.
Generated 2/24/24, 9:32 AM